NASDAQ:ENSC

Ensysce Biosciences (ENSC) Stock Forecast, Price & News

$2.32

-0.05 (-2.11%)

(As of 05/26/2023 08:46 PM ET)

Compare

Today's Range: $2.31
▼
$2.40
50-Day Range: $2.32
▼
$58.32
52-Week Range: $2.29
▼
$220.80

Volume: 28,400 shs
Average Volume: 1.63 million shs
Market Capitalization: $2.97 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.00

Ensysce Biosciences MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 546.6% Upside
$15.00 Price Target
Short Interest: Bearish
11.03% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.43
Based on 2 Articles This Week
Insider Trading: Acquiring Shares
$44,235 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($13.00) to ($15.25) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.97 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Ensysce Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $15.00, Ensysce Biosciences has a forecasted upside of 546.6% from its current price of $2.32.
Amount of Analyst Coverage
Ensysce Biosciences has received no research coverage in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
11.03% of the float of Ensysce Biosciences has been sold short.
Short Interest Ratio / Days to Cover
Ensysce Biosciences has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Ensysce Biosciences has recently increased by 43.80%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Ensysce Biosciences does not currently pay a dividend.
Dividend Growth
Ensysce Biosciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ENSC.

1.9

News and Social Media Coverage

News Sentiment
Ensysce Biosciences has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Ensysce Biosciences this week, compared to 2 articles on an average week.
Search Interest
8 people have searched for ENSC on MarketBeat in the last 30 days. This is an increase of 60% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Ensysce Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $44,235.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
39.40% of the stock of Ensysce Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Ensysce Biosciences are expected to decrease in the coming year, from ($13.00) to ($15.25) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Ensysce Biosciences is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Ensysce Biosciences is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Ensysce Biosciences (NASDAQ:ENSC) Stock

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.

Receive ENSC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ensysce Biosciences and its competitors with MarketBeat's FREE daily newsletter.

ENSC Stock News Headlines

May 16, 2023 | finance.yahoo.com

ENSC: ENSC Provides an Attractive Entry Point

May 15, 2023 | finance.yahoo.com

Ensysce Biosciences Reports First Quarter 2023 Financial Results

May 30, 2023 | Edge On The Street (Ad)

New "Mined in America" Lithium Opportunities?

The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.

May 12, 2023 | finance.yahoo.com

Ensysce Biosciences, Inc. Announces Closing of $7 Million Public Offering

May 10, 2023 | msn.com

Ensysce Biosciences down 12%, prices $7M offering

May 10, 2023 | finance.yahoo.com

Ensysce Biosciences, Inc. Announces Pricing of $7 Million Public Offering

May 9, 2023 | msn.com

ENSC: ENSC Announces Potential Game-Changing Results

May 9, 2023 | finance.yahoo.com

Why Are Ensysce Biosciences Shares Are Trading Higher Today

May 30, 2023 | Edge On The Street (Ad)

The Graphite Shortage Story You're Not Being Told

Graphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security.

May 9, 2023 | investorplace.com

Why Is Ensysce Biosciences (ENSC) Stock Up 50% Today?

May 9, 2023 | finanznachrichten.de

Ensysce Biosciences, Inc.: Ensysce Biosciences Announces Successful Completion of Ground-Breaking Study on Overdose Protection

May 9, 2023 | finance.yahoo.com

Ensysce Biosciences Announces Successful Completion of Ground-Breaking Study on Overdose Protection

April 19, 2023 | finance.yahoo.com

Ensysce CEO Dr. Lynn Kirkpatrick To Present Featured Case Study of MPAR Overdose Protection Platform Accelerated Development

April 15, 2023 | americanbankingnews.com

Ensysce Biosciences (NASDAQ:ENSC) PT Lowered to $15.00 at Lake Street Capital

April 11, 2023 | finanznachrichten.de

Ensysce Biosciences, Inc.: Ensysce Biosciences Announces Updated Investor Presentation Available Via Investor Relations Website

April 11, 2023 | finance.yahoo.com

Ensysce Biosciences Announces Updated Investor Presentation Available Via Investor Relations Website

April 9, 2023 | americanbankingnews.com

Q1 2023 EPS Estimates for Ensysce Biosciences, Inc. (NASDAQ:ENSC) Increased by Analyst

April 5, 2023 | finanznachrichten.de

Ensysce Biosciences, Inc.: Ensysce Biosciences Announces Positive Results from Oral Human Abuse Potential Trial for PF614

April 3, 2023 | finance.yahoo.com

ENSC: Ensysce Provides Positive Result on Non-Addictive Opioid

April 3, 2023 | msn.com

Ensysce stock jumps ~10% after pain drug PF614 meets key goal in trial

April 3, 2023 | finance.yahoo.com

Ensysce Biosciences Announces Positive Results from Oral Human Abuse Potential Trial for PF614

April 3, 2023 | americanbankingnews.com

Altimmune (NASDAQ:ALT) & Ensysce Biosciences (NASDAQ:ENSC) Head to Head Survey

April 2, 2023 | benzinga.com

Ensysce Biosciences Inc Down 25.05% To $5.09 After Earnings Beat

March 30, 2023 | finanznachrichten.de

Ensysce Biosciences, Inc.: Ensysce Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results

March 30, 2023 | finance.yahoo.com

Ensysce Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results

March 24, 2023 | finanznachrichten.de

Ensysce Biosciences, Inc.: Ensysce Biosciences Announces Completion of Enrollment for Groundbreaking Opioid Overdose Protection Study

March 22, 2023 | finance.yahoo.com

Ensysce Biosciences Announces Completion of Enrollment for Groundbreaking Opioid Overdose Protection Study

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ENSC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ensysce Biosciences and its competitors with MarketBeat's FREE daily newsletter.

ENSC Company Calendar

Today: 5/30/2023
Next Earnings (Estimated): 8/10/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ENSC
CUSIP: N/A
CIK: 1716947
Web: ensysce.com
Phone: 858-263-4196
Fax: N/A
Employees: 4
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $15.00
High Stock Price Forecast: $15.00
Low Stock Price Forecast: $15.00
Forecasted Upside/Downside: +546.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($139.5350)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-24,170,000.00
Net Margins: -944.85%
Pretax Margin: -938.73%
Return on Equity: N/A
Return on Assets: -577.27%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.85
Quick Ratio: 0.85

Sales & Book Value

Annual Sales: $2.52 million
Price / Sales: 1.18
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($7.54) per share
Price / Book: -0.31

Miscellaneous

Outstanding Shares: 1,280,000
Free Float: 779,000
Market Cap: $2.97 million
Optionable: Not Optionable
Beta: 0.58

Key Executives

Dr. D. Lynn Kirkpatrick Ph.D. (Age 65)
Pres, CEO & Director
Comp: $288.15k

Mr. David C. Humphrey CPA (Age 54)
CFO, Sec. & Treasurer
Comp: $308.41k

Mr. Geoffrey Birkett (Age 60)
Chief Commercial Officer
Comp: $135k

Dr. Jeffrey Millard Ph.d. (Age 47)
Chief Operating Officer

Mr. Richard Wright M.B.A. (Age 50)
MSE, Chief Bus. Officer

Dr. William K. Schmidt Ph.D. (Age 71)
Chairman of Clinical Advisory Board & Chief Medical Officer

Dr. Linda Pestano Ph.D. (Age 53)
Chief Devel. Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ENSC Stock - Frequently Asked Questions

Should I buy or sell Ensysce Biosciences stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ensysce Biosciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ENSC shares.
View ENSC analyst ratings or view top-rated stocks.
What is Ensysce Biosciences' stock price forecast for 2023?: 1 equities research analysts have issued 1 year target prices for Ensysce Biosciences' stock. Their ENSC share price forecasts range from $15.00 to $15.00. On average, they predict the company's stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 546.6% from the stock's current price.
View analysts price targets for ENSC or view top-rated stocks among Wall Street analysts.
How have ENSC shares performed in 2023?: Ensysce Biosciences' stock was trading at $9.00 at the beginning of the year. Since then, ENSC stock has decreased by 74.2% and is now trading at $2.32.
View the best growth stocks for 2023 here.
Are investors shorting Ensysce Biosciences?: Ensysce Biosciences saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 113,600 shares, an increase of 43.8% from the April 30th total of 79,000 shares. Based on an average daily volume of 664,800 shares, the days-to-cover ratio is currently 0.2 days. Currently, 11.0% of the shares of the company are sold short.
View Ensysce Biosciences' Short Interest.
When is Ensysce Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our ENSC earnings forecast.
When did Ensysce Biosciences' stock split?: Shares of Ensysce Biosciences reverse split before market open on Friday, March 31st 2023. The 1-12 reverse split was announced on Friday, March 31st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 31st 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What is Ensysce Biosciences' stock symbol?: Ensysce Biosciences trades on the NASDAQ under the ticker symbol "ENSC."
Who are Ensysce Biosciences' major shareholders?: Ensysce Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (1.05%).
View institutional ownership trends.
How do I buy shares of Ensysce Biosciences?: Shares of ENSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Ensysce Biosciences' stock price today?: One share of ENSC stock can currently be purchased for approximately $2.32.
How much money does Ensysce Biosciences make?: Ensysce Biosciences (NASDAQ:ENSC) has a market capitalization of $2.97 million and generates $2.52 million in revenue each year. The company earns $-24,170,000.00 in net income (profit) each year or ($139.5350) on an earnings per share basis.
How can I contact Ensysce Biosciences?: Ensysce Biosciences' mailing address is 250 WEST 57 TH STREET SUITE 415, NEW YORK NY, 10107. The official website for the company is ensysce.com. The company can be reached via phone at 858-263-4196 or via email at shannon@mzgroup.us.

This page (NASDAQ:ENSC) was last updated on 5/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial